HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boots charts Clearasil course

This article was originally published in The Rose Sheet

Executive Summary

UK-based Boots will devote additional $171 mil. (?1=$1.42) to support its three "core" brands, including Clearasil, Strepsils medicated lozenges and Nuraphen analgesics, over the next four years, company says. Increased support is part of effort to boost Boots' profit from organic growth from $84.9 mil. to $142.5 mil. within four years. Additional support will be split between marketing and new product development, company says. New ads for Clearasil, designed by Grey Global Group, will debut in the U.S. in May and feature a more "contemporary" perspective on acne, according to Boots. Four new Clearasil products also are slated to bow stateside later this year, according to the firm. Boots acquired Clearasil from Procter & Gamble in 2000 (1"The Rose Sheet" Oct. 23, 2000, p. 3)...

You may also be interested in...



Boots Healthcare Gains Access To U.S. Market Through Clearasil Buy

Boots Healthcare International views its acquisition of the Clearasil acne prevention and treatment brand as a possible springboard for creating an OTC drug marketing presence in the U.S.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

RS010059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel